US · ATHE
Alterity Therapeutics Limited
- Sector
- Healthcare · Biotechnology
- Headquarters
- Melbourne, VIC 3000
- Website
- alteritytherapeutics.com
Price · as of 2025-06-30
$4.73
Market cap 31.19M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $13.50 | +185.71% |
| Intrinsic Value(DCF) | $3.55 | -24.87% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $93.00 | $69.77 | $1.84 | $0.00 | $184.50 |
| 2012 | $103.80 | $79.52 | $0.00 | $0.00 | $0.00 |
| 2013 | $306.00 | $139.12 | $5.94 | $0.00 | $92.50 |
| 2014 | $152.40 | $157.47 | $22.86 | $0.00 | $0.00 |
| 2015 | $52.20 | $222.18 | $19.74 | $7.60 | $188.80 |
| 2016 | $51.60 | $319.94 | $14.89 | $0.00 | $59.40 |
| 2017 | $26.10 | $200.71 | $10.99 | $0.00 | $0.00 |
| 2018 | $20.10 | $15.77 | $5.19 | $0.00 | $0.00 |
| 2019 | $10.20 | $50.86 | $1.22 | $0.00 | $273.80 |
| 2020 | $19.50 | $178.09 | |||
| 2021 | $13.20 | $3.56 | $0.00 | ||
| 2022 | $5.70 | $60.96 | $2.79 | $0.00 | $0.00 |
| 2023 | $2.78 | $23.72 | $0.77 | $0.00 | $32.30 |
| 2024 | $1.24 | $43.00 | $0.00 | $0.00 | $0.00 |
| 2025 | $5.07 | $20.64 | $1.32 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Alterity Therapeutics Limited's (ATHE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $13.50
- Current price
- $4.73
- AI upside
- +185.71%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.55
-24.87% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ATHE | Alterity Therapeutics Lim… | $4.73 | 31.19M | +337% | -25% | — | — | -6.79 | 1.95 | 15.18 | -2.87 | — | 1.95 | 97.66% | -267.96% | -223.35% | -43.23% | -905.76% | -37.23% | 0.00 | — | 12.98 | 12.62 | 2.26 | -6346.00% | 3532.00% | -920.00% | -13.87% | -3.24 | -711.67% | 0.00% | 0.00% | 24.86% | -2.88 | -3.67 | 7.73 | 6.97 |
| ANVS | Annovis Bio, Inc. | $2.68 | 52.73M | — | — | — | — | 0.00 | 2.28 | — | -0.40 | 0.00 | 2.28 | 0.00% | — | — | -3159092.37% | 361.97% | -203782.88% | 0.00 | -14.40 | 3.59 | 2.72 | 0.40 | 3215955.00% | — | 5468129.00% | -103292.61% | -5641.50 | 296879.29% | 0.00% | 0.00% | 22.63% | -0.40 | 0.00 | — | -16.26 |
| BTAI | BioXcel Therapeutics, Inc… | $1.67 | 36.52M | +9,886% | -19% | — | — | -0.14 | -0.09 | 3.77 | -1.85 | — | -0.09 | 5.43% | -2967.56% | -2630.14% | 79.67% | 333.28% | -106.39% | -1.11 | -4.44 | 1.68 | 1.35 | -1.66 | -7610.00% | 6420.00% | -5354.00% | -843.12% | -3.24 | 356.98% | 0.00% | 0.00% | 0.00% | -1.21 | -1.13 | 36.03 | -28.96 |
| DYAI | Dyadic International, Inc… | $0.78 | 28.19M | +4,253% | -26% | — | — | -7.32 | 17.21 | 12.16 | -7.12 | — | 17.21 | 65.82% | -168.82% | -166.19% | -139.16% | 396.74% | -64.01% | 2.05 | -13.79 | 4.01 | 3.88 | 0.27 | -1667.00% | 2058.00% | -4091.00% | -9.35% | -1.62 | 267.25% | 0.00% | 0.00% | 0.00% | -6.49 | -9.64 | 10.96 | -9.43 |
| EVAX | Evaxion Biotech A/S | $3.16 | 19.96M | +25,906% | -76% | — | — | -0.19 | -1.22 | 0.60 | -0.72 | — | -1.22 | 100.00% | -440.55% | -316.00% | 331.20% | -693.28% | -83.29% | -6.11 | -15.31 | 2.01 | 1.58 | -0.52 | -6975.00% | 448082.00% | -2721.00% | -641.54% | -2.96 | -654.36% | 0.00% | 0.00% | 11.80% | -0.48 | -0.55 | 2.11 | -16.41 |
| GBIO | Generation Bio Co. | $5.34 | 35.98M | +46% | -60% | — | — | -0.27 | 0.41 | 1.78 | 0.76 | -40.69 | 0.41 | 100.00% | -715.82% | -661.91% | -91.02% | -912.79% | -43.46% | 1.09 | — | 5.50 | 5.33 | -0.23 | 66.00% | 23692.00% | 5125.00% | -256.40% | -2.53 | -583.12% | 0.00% | 0.00% | 39.99% | 0.39 | 0.62 | -2.82 | -5.24 |
| LIMN | Liminatus Pharma, Inc. Cl… | $0.25 | 7.86M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 21.87% | 87.68% | -79.23% | -0.32 | -21.04 | 0.09 | 0.09 | -1.57 | 16667.00% | — | -713.00% | — | -0.36 | 93.72% | — | 0.00% | — | — | — | — | — |
| MURA | Mural Oncology plc | $2.04 | 35.38M | — | — | — | — | -0.48 | 0.44 | — | 0.60 | — | 0.44 | 0.00% | — | — | -63.57% | -2282.87% | -54.55% | 0.06 | — | 5.84 | 5.51 | 0.86 | -3902.00% | — | -3493.00% | -209.58% | -4.91 | -2123.95% | 0.00% | 0.00% | 0.00% | 0.54 | 0.58 | — | -1.84 |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
- CEO
- David A. Stamler
- Employees
- 10
- Beta
- -0.02
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.55 ÷ $4.73) − 1 = -24.87% (DCF, example).